Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
Lucy Gilbert, MD, MSc, professor, Department of Obstetrics & Gynecology and the Department of Oncology, McGill University and director of Gynecologic Oncology and Women’s Health Research Unite, McGill University Health Centre, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab (Avastin) in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
The overall response rate (ORR) was 47%, but in patients with high folate receptor alpha (FRα) expression, the ORR was 64%, which is a very encouraging finding. When looking at the subgroup of patients with high FRα-expression, the ORR is 59% among those with platinum-resistant disease, which is almost double what has been seen with other agents in this setting, says Gilbert. In the platinum-sensitive subset, the ORR is also encouraging at 69%.
Data for progression-free survival and duration of response were still immature, but almost half the patients remained on treatment after a median follow-up of 8.5 months.